Background: Skeletal-related events (SREs; pathologic fracture [PF], spinal cord compression and radiation or surgery to bone) are common complications of bone metastases or bone lesions and can impose a considerable burden on patients and healthcare systems. In this study, the healthcare resource utilisation (HRU) associated with PFs in patients with bone metastases or lesions secondary to solid tumours or multiple myeloma was estimated in eight European countries.

Methods: Eligible patients were identified in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. HRU data were extracted from hospital charts from 3.5 months before the index PF (defined as a PF preceded by a 6.5-month period without a SRE) until 3 months after the last SRE during the study period. Changes from baseline in the number and duration of inpatient stays, number of outpatient visits and number of procedures provided were recorded.

Results: Overall, 118 patients with PFs of long bones (those longer than they are wide, e.g. the femur) and 241 patients with PFs of other bones were included. Overall, HRU was greater in patients with long bone PFs than in those with PFs of other bones. A higher proportion of patients with long bone PFs had multiple SREs (79.7%), and more of their SREs were considered to be linked (73.4%) compared with patients with PFs of other bones (51.0% and 47.2%, respectively).

Conclusion: The increased number and duration of inpatient stays for PFs of long bones compared with those for PFs of other bones may be due in part to the requirement for complicated and lengthy rehabilitation in patients with long bone PFs. Implementing strategies to delay or reduce the number of PFs experienced by patients with bone metastases or lesions may therefore reduce the associated HRU and patient burden.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154698PMC
http://dx.doi.org/10.1016/j.jbo.2016.07.003DOI Listing

Publication Analysis

Top Keywords

pfs bones
16
bone metastases
12
patients pfs
12
patients long
12
long bone
12
bone pfs
12
pfs
11
patients
10
pathologic fracture
8
healthcare resource
8

Similar Publications

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.

Eur J Cancer

January 2025

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

Background: About 15-20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of cancer progression while maintaining the same systemic treatment, aiming to prolong the time to next systemic treatment (NEST). This study aims to assess the outcomes provided by this multimodal strategy.

View Article and Find Full Text PDF

SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) in the chest is a high-grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4-UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy.

View Article and Find Full Text PDF

Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones. This study aimed to describe the clinical characteristics and outcomes of patients with mCRPC treated with radium-223 in a real-world setting. This was a retrospective study of patients with mCRPC treated with radium-223 between 2016 and 2020 at the London Health Sciences Centre in London, Canada.

View Article and Find Full Text PDF

Background: Spheno-orbital meningiomas (SOM) are known to invaded critical skull base areas. The authors report a series of WHO I SOM, propose a subclassification of this tumor according to its extension to critical positions and analyze the impact of extent of resection and the role of stereotactic radiotherapy in tumor recurrence.

Methods: A prospective maintained university medical center registry was utilized to undertake a retrospective review of patients operated with WHO I SOM.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the efficacy and safety of molecular-targeted agents for treating recurrent or metastatic adenoid cystic carcinoma (R/M ACC), as there is no consensus on their effectiveness.
  • A systematic review included 28 studies with 849 patients, analyzing key outcomes like the objective response rate (ORR) and progression-free survival (PFS), highlighting that multiple kinase inhibitors (MKIs) show improved results compared to other targeted therapies.
  • The study found a low pooled ORR of 4.0% but a high disease control rate (DCR) of 80.5%, and identified fatigue, hypertension, and nausea as the most common adverse effects, suggesting potential benefits of combining MKIs with immune checkpoint inhibitors for better
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!